CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.51%
This Quarter Est. Return
1 Year Est. Return
+11.51%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$230M
AUM Growth
-$14.4M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
31
New
Increased
Reduced
Closed

Top Buys

1
+$18M
2
+$15.5M
3
+$14.9M
4
ROIV icon
Roivant Sciences
ROIV
+$13.1M
5
VRNA
Verona Pharma
VRNA
+$10.2M

Top Sells

1
+$22.4M
2
+$20.5M
3
+$18.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$15.1M
5
RPRX icon
Royalty Pharma
RPRX
+$12.7M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$88.8B
$18M 7.83%
+295,000
AMGN icon
2
Amgen
AMGN
$161B
$15.6M 6.78%
50,000
+11,910
BIIB icon
3
Biogen
BIIB
$21B
$15.5M 6.76%
+113,500
LLY icon
4
Eli Lilly
LLY
$720B
$14.9M 6.47%
+18,000
INSM icon
5
Insmed
INSM
$35B
$14.2M 6.19%
186,384
-24,500
RARE icon
6
Ultragenyx Pharmaceutical
RARE
$3.14B
$13.7M 5.98%
379,303
-27,500
BBIO icon
7
BridgeBio Pharma
BBIO
$10.5B
$13.5M 5.88%
390,644
-169,700
PRGO icon
8
Perrigo
PRGO
$2.97B
$13.4M 5.85%
479,517
+185,000
ROIV icon
9
Roivant Sciences
ROIV
$11.8B
$13.1M 5.71%
+1,300,000
TEVA icon
10
Teva Pharmaceuticals
TEVA
$22.2B
$12.3M 5.37%
801,806
+216,923
RPRX icon
11
Royalty Pharma
RPRX
$16B
$11.1M 4.84%
356,894
-407,965
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.08B
$10.5M 4.59%
205,000
+92,500
VRNA
13
DELISTED
Verona Pharma
VRNA
$10.2M 4.42%
+160,000
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$9.78B
$7.95M 3.46%
+24,000
SMMT icon
15
Summit Therapeutics
SMMT
$15.6B
$7.72M 3.36%
+400,000
HALO icon
16
Halozyme
HALO
$7.84B
$7.66M 3.33%
+120,000
CYTK icon
17
Cytokinetics
CYTK
$6.99B
$7.03M 3.06%
+175,000
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.46B
$6.9M 3%
235,350
-66,273
CNTA
19
Centessa Pharmaceuticals
CNTA
$3.09B
$6.01M 2.62%
418,127
+271,051
RCUS icon
20
Arcus Biosciences
RCUS
$1.75B
$5.74M 2.5%
+731,818
NAMS icon
21
NewAmsterdam Pharma
NAMS
$4.1B
$4.53M 1.97%
221,152
-116,000
ABBV icon
22
AbbVie
ABBV
$406B
– –
-101,996
AKRO icon
23
Akero Therapeutics
AKRO
$4.32B
– –
-230,000
JANX icon
24
Janux Therapeutics
JANX
$1.61B
– –
-120,000
JNJ icon
25
Johnson & Johnson
JNJ
$465B
– –
-141,572
1
2